Troels Koch (TK) has 20 years’ experience in the international life science and biopharmaceutical industry. Founder of several biotech companies of which Exiqon A/S and Santaris Pharma A/S are the most commonly known. Santaris Pharma A/S was successfully exited in August 2014 – acquired by Roche, and Exiqon A/S was acquired in 2016 by Qiagen. TK has been positioned in company management teams and taken part in all aspects of executive decision making: Company strategy, VC fundraising, deal makings, partnering, IP strategy & prosecution, drug discovery and R&D. TK pioneered LNA therapeutics and has been responsible for keeping LNA antisense science and technology at an international lead position. He has worked with RNA therapeutics for 20 years and taken an active role in all steps of oligonucleotide drug discovery and development. TK has built R&D organizations up to 75 co-workers, held 100+ invited presentations at international conferences and is author of 80+ peer reviewed publications.
Guillermo A. Morales, Ph.D., MBA Conference Co-Chairman - Drug Discovery 2020
Chief Executive Officer, Innoventyx, Oro Valley, Arizona
Dr. Guillermo Morales, PhD, MBA, is the CEO of Innoventyx, LLC (www.innoventyx.com), a renowned international consulting firm assisting dozens of life science and pharmaceutical companies, executives and teams throughout all the drug development stages: from conception through commercialization. This includes, though is not limited to, research, development, operations, global management/business development (USA, Asia, Russia, Latin America, etc), grants, licensing, fundraising, intellectual property and sales. Dr. Morales earned his PhD in Organic Chemistry at Louisiana State University and an MBA with Welch Scholar Distinction (GPA: 4.0/4.0) from the Jack Welch Management Institute at Strayer University. He has over 24 years of experience successfully working with large, medium and small pharmaceutical and biotech companies for a broad range of research programs and disease indications (e.g., cancer, anti-infectives, CNS, cardiovascular, metabolic, etc). In addition, the breadth and depth of his experience and skills include medicinal chemistry, computer-aided drug design (e.g., single target, multi-specific targets, new mode of action, undruggable targets), high-throughput synthesis, chemoinformatics, ADME/Tox, IND-enabling studies. He is the leading inventor in 9 granted patents (plus 4 applications), author in 34 scientific publications, former Editor-in-Chief of the journal Molecular Diversity (11 years), and since 2018 Dr. Morales serves as an SBIR reviewer for the National Institutes of Health (NIH).
Lisa L. Braun, DC, MS Conference Co-Organizer - Drug Discovery-2020
Hester Health Chiropractic PLLC, Orchard Park, NY
Dr. Lisa L. Braun earned her Doctor of Chiropractic degree from New York Chiropractic College as well as a Masters of Science in Exercise Science with a concentration in Human Performance from Ithaca College. Her Bachelors of Science was obtained from the University at Buffalo in Psychology with a special focus on Behavioral Neuroscience. Dr. Braun has worked in a variety of areas of academic research including Psychology, Exercise Physiology, as well as Biomechanics. Her work in Biomechanics was centered around Barefoot Running, a popular trend at the time. Dr. Braun founded INTELLECAN to provide access to Evidence Based Custom Cannabis Medicine within a Salutogenic Model of Healthcare. Salutogenic Healthcare is a healthcare paradigm that encompasses Functional Medicine as well as Complementary and Alternative Therapies in addition to standard mainstream medical treatments. Dr. Braun is following the advances in Cannabis research and working to identify the therapeutic applications of Major and Minor Cannabinoids as well Cannabis Terpenes. She believes Cannabis Medicine should be delivered through a strict set of standards along with the understanding that human physiology is ever changing and dynamic and that the cannabis plant, with careful oversight, can be applied in a manor that accommodates the fluctuations in Physiology. Dr. Braun is currently working on forming relationships with Universities, Researchers, Pharmacists, Medical Doctors, and other Healthcare providers to join an effort establishing Cannabis Medicine as a new standard of care for chronic pain and other common conditions. She is also hoping to contribute to the pool of practice-based evidence.
Steve VanDeWalle, MBA Conference Co-Organizer - Drug Discovery 2020
Owner & CEO | Tiva, Director of Development | Roc NORML, Rochester, NY
Steve VanDeWalle is a Cannabis entrepreneur and activist from Rochester, NY. He earned his B.S. in Brain and Cognitive Sciences from the University of Rochester, and his MBA from the William G. Simon School of Business at the University of Rochester. He is the Founder and CEO of Tiva Naturals, a lifestyle-wellness brand specializing in the formulation, manufacturing, and selling of craft Cannabis products. He is a founding member and advisor to Roc NORML — the Rochester Chapter for the National Organization for the Reform of Marijuana Laws. Steve is the executive producer and host of #RocNORMLRadio, an educational podcast where political, industry, and academic experts come together to discuss the exciting and rapidly evolving Cannabis industry. To learn more about Steve, visit his website: www.stevevandewalle.com
USG United Scientific Group
A non-profit organization 8105, Suite 112, Rasor Blvd
Plano, TX 75024, USA Fax: +1-469-854-2278 Toll free: +1-844-395-4102